Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Choose from credit cards with zero annual fees that offer cash back rewards. Keep all your rewards and maximize your savings.
23,592 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
The YieldMax COIN Option Income Strategy ETF, ticker CONY, endured a steep 56.25% decline in the latest year, with di...
Delta and United just reported, but the big question remains: what's next airline stocks? This guide breaks down the ...
The data center story now hinges on AI workloads and energy efficiency. This clear, practical comparison of Applied D...
Across software-as-a-service stocks, Wix has been a standout case of a dramatic pullback. This piece breaks down why ...
Ford reveals a heavy Q4 loss tied to Model e impairments, renewing Reddit-driven skepticism about its EV turnaround a...
Kraft Heinz trimmed guidance after a challenging quarter, McCormick posted steady growth with margin pressure, and Ho...
Could a bold thesis around Oklo Inc. unlock life-changing gains? This forward-looking guide breaks down why nuclear e...
Axsome Therapeutics stock keeps climbing, hitting another high as regulatory news and a solid quarterly update bolste...
A new research note sets a bold 2027 price target for Procter & Gamble, arguing efficiency gains and steady demand co...
Tesla and Nvidia remain market favorites as AI bets diverge. Analysts say one stock currently offers a clearer, more ...
Joby Aviation posted record Q4 2025 revenue driven by the Blade acquisition, but the stock remains volatile as cash b...